TY - JOUR
T1 - Chemohormonal therapy in advanced carcinoma of the breast
T2 - Cancer and Leukemia Group B protocol 8081
AU - Perry, M. C.
AU - Kardinal, C. G.
AU - Korzun, A. H.
AU - Ginsberg, S. J.
AU - Raich, P. C.
AU - Holland, J. F.
AU - Ellison, R. R.
AU - Kopel, S.
AU - Schilling, A.
AU - Aisner, J.
AU - Schulman, P.
AU - Weinberg, V.
AU - Rice, M. A.
AU - Wood, W.
PY - 1987
Y1 - 1987
N2 - In a prospective, randomized trial Cancer and Leukemia Group B (CALGB) evaluated CAF chemotherapy (cyclophosphamide + doxorubicin + 5-fluorouracil [5-FU] v CAF plus tamoxifen (TCAF) in advanced breast cancer. Patients were stratified by estrogen receptor (ER) status, dominant site of metastatic disease, menopausal status, and prior adjuvant therapy. Regardless of ER status or menopausal status, the addition of tamoxifen conferred no significant advantage in response rate, response duration, time to treatment failure (TTF) or survival over CAF alone. A secondary objective was to compare the response to CAF or ER positive (ER+) and ER negative (ER-) patients to determine if there was a differential response to cytotoxic chemotherapy. Response rates of ER+ and ER- patients to CAF were identical (56%), but the response duration, time to treatment failure, and survival of ER+ patients were significantly longer than ER- patients. This lack of differential response implies that chemotherapy and hormonal therapy may compete for the same pool of ER+ cells. It also suggests that chemotherapy kills breast cancer cells indiscriminately, regardless of ER status.
AB - In a prospective, randomized trial Cancer and Leukemia Group B (CALGB) evaluated CAF chemotherapy (cyclophosphamide + doxorubicin + 5-fluorouracil [5-FU] v CAF plus tamoxifen (TCAF) in advanced breast cancer. Patients were stratified by estrogen receptor (ER) status, dominant site of metastatic disease, menopausal status, and prior adjuvant therapy. Regardless of ER status or menopausal status, the addition of tamoxifen conferred no significant advantage in response rate, response duration, time to treatment failure (TTF) or survival over CAF alone. A secondary objective was to compare the response to CAF or ER positive (ER+) and ER negative (ER-) patients to determine if there was a differential response to cytotoxic chemotherapy. Response rates of ER+ and ER- patients to CAF were identical (56%), but the response duration, time to treatment failure, and survival of ER+ patients were significantly longer than ER- patients. This lack of differential response implies that chemotherapy and hormonal therapy may compete for the same pool of ER+ cells. It also suggests that chemotherapy kills breast cancer cells indiscriminately, regardless of ER status.
UR - http://www.scopus.com/inward/record.url?scp=0023472371&partnerID=8YFLogxK
U2 - 10.1200/JCO.1987.5.10.1534
DO - 10.1200/JCO.1987.5.10.1534
M3 - Article
C2 - 3655856
AN - SCOPUS:0023472371
SN - 0732-183X
VL - 5
SP - 1534
EP - 1545
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 10
ER -